Business, energy, technology, markets and global industry news from Business News Today

type 2 diabetes mellitus

PharmaDeviceNews type 2 diabetes mellitus
Representative image: Generic semaglutide injection pens on a clinical desk with Canadian healthcare cues, reflecting Dr. Reddy’s Laboratories’ launch of generic semaglutide injection in Canada and the growing focus on GLP-1 access for type 2 diabetes treatment.
Pharma & Biotech

Dr. Reddy’s moves first in Canada’s generic semaglutide market. Can access improve?

GLP-1 demand is booming, but access remains uneven. Dr. Reddy’s Canada launch tests whether generics can change semaglutide economics.

Read More
Pharma & Biotech

Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?

Oral GLP-1s promise convenience, but proof is still clinical. Ascletis’ ASC30 diabetes trial could test whether hype can meet HbA1c data.

Read More